Sage/Biogen See Big Potential Market For Zuranolone In PPD

SKYLARK Meets Primary, Key Secondary Endpoints

 
• By Alaric DeArment
Sage and Biogen announced results of the Phase III SKYLARK trial of zuranolone in postpartum depression • Source: Shutterstock

More from Strategy

More from Business